Recipharm Collaborates with Laccure AB

Author(s)Pharmaceutical Technology Editors

Recipharm and Laccure AB signed a commercial collaboration for the manufacture and delivery of Laccure’s bacterial vaginosis treatment.

On Dec. 1, 2016 Recipharm announced that it has entered a commercial collaboration with Laccure AB for the manufacture and delivery of Laccure Pessary, a non-prescription vaginal tablet for the treatment of bacterial vaginosis. Laccure Pessary will be manufactured, packaged, and distributed globally from Recipharm’s facility in Karlskoga that specializes in the production of semi-solid products. Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure Pessary, and the exact date for the launch will be announced in 2017. Laccure Pessary is based on a patented substance that releases lactic acid.

Source: Recipharm

Articles in this issue

almost 9 years ago

Article

Factors to Consider in Dissolution Testing

almost 9 years ago

Article

Internal and External Factors to Shape CMO Industry

almost 9 years ago

Article

New Opportunities for Cocrystals

almost 9 years ago

Article

Analytical Method Validation Using QbD and QRM

almost 9 years ago

Article

Vetter Processing Center Receives Data Certification

almost 9 years ago

Article

Idifarma Invests in Automatic Capsule Filling Capabilities

almost 9 years ago

Article

Catalent Expands Softgel Capacity with Accucaps Acquisition

almost 9 years ago

Article

Patheon Acquires Roche API Site

almost 9 years ago

Article

FDA Guidance Helps Further Clarify Quality Agreements

almost 9 years ago

Article

PCI Expands Cryogenic Storage Facilities to Rockford Site

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!